Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia
Authors
Keywords
-
Journal
LEUKEMIA
Volume 29, Issue 4, Pages 877-885
Publisher
Springer Nature
Online
2014-10-07
DOI
10.1038/leu.2014.297
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Subclonal variant calling with multiple samples and prior knowledge
- (2014) M. Gerstung et al. BIOINFORMATICS
- Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia
- (2014) D. Rossi et al. BLOOD
- Targeted resequencing for analysis of clonal composition of recurrent gene mutations in chronic lymphocytic leukaemia
- (2013) Alexander Jethwa et al. BRITISH JOURNAL OF HAEMATOLOGY
- Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia
- (2013) Dan A. Landau et al. CELL
- Clonal Evolution, Genomic Drivers, and Effects of Therapy in Chronic Lymphocytic Leukemia
- (2013) P. Ouillette et al. CLINICAL CANCER RESEARCH
- The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab
- (2013) Anna Panovská et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Mechanism of somatic hypermutation at the WA motif by human DNA polymerase
- (2013) Y. Zhao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia
- (2012) D. Rossi et al. BLOOD
- ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia
- (2012) S Pospisilova et al. LEUKEMIA
- Reliable detection of subclonal single-nucleotide variants in tumour cell populations
- (2012) Moritz Gerstung et al. Nature Communications
- Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL
- (2011) X. C. Badoux et al. BLOOD
- Missense Mutations Located in Structural p53 DNA-Binding Motifs Are Associated With Extremely Poor Survival in Chronic Lymphocytic Leukemia
- (2011) Martin Trbusek et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutational Status of theTP53Gene As a Predictor of Response and Survival in Patients With Chronic Lymphocytic Leukemia: Results From the LRF CLL4 Trial
- (2011) David Gonzalez et al. JOURNAL OF CLINICAL ONCOLOGY
- Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
- (2011) Xose S. Puente et al. NATURE
- Understanding and Managing Ultra High-Risk Chronic Lymphocytic Leukemia
- (2011) S. Stilgenbauer et al. Hematology-American Society of Hematology Education Program
- Aggressive Chronic Lymphocytic Leukemia with Elevated Genomic Complexity Is Associated with Multiple Gene Defects in the Response to DNA Double-Strand Breaks
- (2010) P. Ouillette et al. CLINICAL CANCER RESEARCH
- TP53Mutation and Survival in Chronic Lymphocytic Leukemia
- (2010) Thorsten Zenz et al. JOURNAL OF CLINICAL ONCOLOGY
- TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations
- (2010) T Zenz et al. LEUKEMIA
- TP53 Mutations are infrequent in newly diagnosed chronic lymphocytic leukemia
- (2010) Norafiza Zainuddin et al. LEUKEMIA RESEARCH
- Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage
- (2009) J. Malcikova et al. BLOOD
- Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial
- (2009) T. Zenz et al. BLOOD
- De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience
- (2009) C. S. Tam et al. BLOOD
- The Prognostic Value of TP53 Mutations in Chronic Lymphocytic Leukemia Is Independent of Del17p13: Implications for Overall Survival and Chemorefractoriness
- (2009) D. Rossi et al. CLINICAL CANCER RESEARCH
- Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group
- (2009) Stephan Stilgenbauer et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now